The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient

This study has been completed.
Sponsor:
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00000661
First received: November 2, 1999
Last updated: August 1, 2008
Last verified: December 1994

November 2, 1999
August 1, 2008
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00000661 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient
The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient

To determine if a pharmacokinetic (blood level) interaction exists between zidovudine (AZT) and oxazepam in the HIV-infected patient. Benzodiazepines (such as oxazepam) are among the most frequently prescribed class of drugs and are commonly used therapeutically for patients with chronic disease. This study is important because of the potential for toxicity resulting from a reaction between AZT and benzodiazepines and the likelihood of frequent use of the combination of these drugs in patients with HIV infection.

Benzodiazepines (such as oxazepam) are among the most frequently prescribed class of drugs and are commonly used therapeutically for patients with chronic disease. This study is important because of the potential for toxicity resulting from a reaction between AZT and benzodiazepines and the likelihood of frequent use of the combination of these drugs in patients with HIV infection.

Patients are studied to determine oral and intravenous AZT and single oral dose oxazepam pharmacokinetics. Patients then take AZT and oxazepam together to determine if interactions between the drugs occur.

Interventional
Phase 1
Endpoint Classification: Pharmacokinetics Study
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
  • Drug: Oxazepam
  • Drug: Zidovudine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
8
Not Provided
Not Provided

Inclusion Criteria

Concurrent Medication:

Required:

  • Stable prescribed dosage of zidovudine (AZT), = or > 500 mg/day.

Allowed:

  • Prophylaxis for Pneumocystis carinii pneumonia (PCP) with aerosolized pentamidine.
  • Erythropoietin.

Patients must be:

  • HIV positive by ELISA and Western blot.
  • Currently taking a stable prescribed dosage of 500 mg/day of zidovudine (AZT).

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day.
  • Significant underlying medical condition that could impair continuous participation in study.
  • Malabsorption syndrome (3 or more loose stools a day for at least 4 weeks associated with an unintentional weight loss of at least 10 percent of body weight).

Concurrent Medication:

Excluded:

  • Oral contraceptives.
  • Cytotoxic chemotherapy.
  • Ganciclovir.
  • Flucytosine.
  • Probenecid.
  • Opiates.
  • Valproic acid.
  • Sulfa drugs.
  • Sucralfate.
  • Dapsone.
  • Rifampin.
  • Antacids within 2 hours of zidovudine (AZT) dose.
  • Isoniazid.
  • Ketoconazole.
  • Pyrimethamine.
  • Clindamycin.
  • Aspirin.
  • Ibuprofen.
  • Investigational drugs not specifically allowed.

Patients with the following are excluded:

  • Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day.
  • Significant underlying medical condition that could impair continuous participation in study.
  • Unable to take oral medication reliably.

Prior Medication:

Excluded within 30 days of study entry:

  • Antiretroviral agents other than zidovudine (AZT).
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00000661
ACTG 124
Not Provided
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Study Chair: Israelski D
Study Chair: Blaschke T
National Institute of Allergy and Infectious Diseases (NIAID)
December 1994

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP